Retatrutide for Obesity
Retatrutide produced large, dose-dependent weight loss in an early clinical trial, but it remains an investigational drug that no regulator has approved, so it is not a treatment you can legally obtain or be prescribed today.
Why this grade7-layer evidence engine
The efficacy signal is genuinely strong. A high-quality 48-week Phase 2 randomized, double-blind, placebo-controlled trial (Jastreboff et al., 2023; PMID 37366315; n=338) found dose-dependent weight loss reaching about 24% at the 12 mg dose versus roughly 2% on placebo, among the largest reductions seen with this drug class. Gastrointestinal side effects (nausea, vomiting, diarrhea) were the most common and increased with dose.
The grade is held to Weak Evidence for two reasons. First, the evidence base is thin: a single Phase 2 trial, with no peer-reviewed Phase 3 publication yet (the 2026 TRIUMPH-1 topline is a press release only, not a citable study). Second, the trial was funded by the manufacturer, Eli Lilly, which the engine flags as an industry-funding concern.
Crucially, efficacy and availability are separate questions. The FDA, EU/EFSA, and other regulators all classify retatrutide as an investigational, unapproved medication still in trials; no clinical authority recommends it. There is no legal consumer or prescription product. Any 'research peptide' sold online is an unregulated, unverified product and should never be self-injected. Approved options such as semaglutide or tirzepatide are the current evidence-based choices.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.53
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status